Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Business Segments — Interest Expense, Nonoperating

Similar metrics at other companies

Booking Holdings Inc. logo
BKNGReportable Segment — Interest Expense, Nonoperating
$253M-61.0%
DocuSign logo
DOCUReportable Segment — Interest Expense, Nonoperating
$636.5K+64.3%
Intuitive Machines, Inc. logo
LUNRReportable Segment — Interest Expense, Nonoperating
$4.89M+18,688%
Andersen Group logo
ANDGReportable Segment — Interest Expense, Nonoperating
$6.23M+4,259%
Opendoor Technologies Inc logo
OPENReportable Segment — Interest Expense, Nonoperating
$23M-30.3%
VGN
VGNTReportable Segment — Interest Expense, Nonoperating
$5M+150%

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$686.48M+7.3%
Enterprise value$542.65M-17.1%
P/E11.8×-230×
P/S-5.3×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025
Gain on sale of PRV148,325148,325
Loss on extinguishment of debt(2,756)
Loss on derivative liability(7,216)
Interest expense(2,009)(1,711)(3,978)
Fair value adjustment related to warrant and CVR liability(6,408)(747)(5,440)4,127
Fair value adjustment related to investments(140)(2)(356)(5)
Interest and other income, net2,5652,3786,1552,921
Total other (expense) income(3,983)147,945(11,324)151,390

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s business segments — interest expense, nonoperating?
Zevra Therapeutics, Inc. (ZVRA) reported business segments — interest expense, nonoperating of $0 in Q2 2026.
How has Zevra Therapeutics, Inc.'s business segments — interest expense, nonoperating changed year-over-year?
Zevra Therapeutics, Inc.'s business segments — interest expense, nonoperating decreased by 100.0% year-over-year, from $2.01M to $0.
What does business segments — interest expense, nonoperating mean?
Captures the interest costs incurred on debt obligations that are not directly tied to core operating activities. It serves as a measure of the segment's financial leverage and the cost of servicing its capital structure.

Ask your AI about Zevra Therapeutics, Inc.'s business segments — interest expense, nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude